Filing Flows › Comparisons › ZNTL vs SEPN
Zentalis Pharmaceuticals vs Septerna: ZNTL and SEPN compared
Zentalis Pharmaceuticals is the larger company: $26.9M of revenue in its latest quarter (Q4 2024) against $26.7M for Septerna (Q2 2026). Septerna is more profitable, with an operating margin of -62.9% against -185.6%.
Where the money goes: ZNTL and SEPN
Zentalis Pharmaceuticals (ZNTL) · Q4 2024
Zentalis Pharmaceuticals, Q4 2024: revenue $26.9M, operating margin -185.6%, net loss $47.5M, operating cash flow −$39.7M. The chart follows the revenue to costs, profit and cash.
Septerna (SEPN) · Q2 2026
Septerna, Q2 2026: revenue $26.7M (225× year over year), operating margin -62.9%, net loss $13.0M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
| Zentalis Pharmaceuticals (ZNTL) | Septerna (SEPN) | |
|---|---|---|
| Latest quarter | Q4 2024 | Q2 2026 |
| Revenue | $26.9M | $26.7M |
| Revenue growth, Y/Y | — | 225× |
| Operating margin | -185.6% | -62.9% |
| Net earnings | −$47.5M | −$13.0M |
| Net margin | -176.7% | -48.7% |
| Operating cash flow | −$39.7M | −$22.2M |
Questions
Which is bigger, Zentalis Pharmaceuticals or Septerna?
Zentalis Pharmaceuticals is the larger company: $26.9M of revenue in its latest quarter (Q4 2024) against $26.7M for Septerna (Q2 2026).
Is Zentalis Pharmaceuticals or Septerna growing faster?
Septerna is more profitable, with an operating margin of -62.9% against -185.6%.
More: Zentalis Pharmaceuticals earnings · how Zentalis Pharmaceuticals makes money · Septerna earnings · how Septerna makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 26, 2025; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.